Migraine during breastfeeding
Treatment of acute migraine in a breastfeeding woman. Per American Headache Society 2024, SEMNIM 2023, and LactMed, first-line in nursing mothers – paracetamol 1 g, ibuprofen 400–600 mg. If ineffective – triptans: sumatriptan 50–100 mg (best studied, Hale L2, RID 3.5%) and eletriptan 40 mg (Hale L3, low RID 0.02%). Ergotamine is contraindicated (reduces milk, infant ergotism risk).
ICD-10 G43.97 drugs
Also known as: Migraine treatment while nursing
Drugs used for this condition
- ASumatriptanFirst line · Selective 5-HT1B/1D serotonin receptor agonistAcute migraine in nursing mothers. Per AHS 2024 and SEMNIM 2023, the triptan of choice. Dose 50–100 mg orally at onset, repeat at 2 h if incomplete. Max 200 mg/day.
- BEletriptanSecond line · Triptan, selective 5HT1B/1D receptor agonistMigraine in nursing mothers when sumatriptan is inadequate. Per AHS 2024 – second-line triptan during breastfeeding. Dose 20–40 mg orally, repeat at 2 h. Max 80 mg/day.
- BRizatriptanSecond line · Selective 5-HT1B/1D serotonin receptor agonistMigraine in nursing mothers. Per AHS 2024 – alternative to sumatriptan during breastfeeding. Dose 5–10 mg orally, repeat at 2 h. Max 30 mg/day. Fast onset (30 min).
- CAlmotriptanSecond line · Selective serotonin 5HT1B/1D agonists (triptans)Migraine in a breastfeeding mother. Data on almotriptan during lactation are limited, but available sources rate it compatible: transfer into milk is low (e-lactancia – low risk; LactMed – acceptable with limited experience). First-line acute treatment while breastfeeding is paracetamol and ibuprofen; a triptan is added when these are insufficient. Dose 12.5 mg orally, repeat at 2 hours if symptoms persist, maximum 25 mg/day. For a newborn or preterm infant, the better-studied sumatriptan is preferred. Contraindicated in coronary artery disease, prior myocardial infarction or stroke, and uncontrolled hypertension; frequent use provokes medication-overuse headache.
- CNaratriptanSecond line · Triptan, selective 5HT1B/1D receptor agonistMigraine in nursing mothers. Dose 2.5 mg orally, repeat at 4 h. Max 5 mg/day. Slower than other triptans, longer effect.
- CZolmitriptanSecond line · Triptan, selective 5HT1B/1D receptor agonistMigraine in nursing mothers. Dose 2.5–5 mg orally or 5 mg nasally, repeat at 2 h. Max 10 mg/day. Nasal form – 15-min onset.
Marketing claims without evidence base
The drug is promoted for these uses outside international guidelines. Each entry below is analyzed against AEMPS, FDA, EMA, Cochrane and major RCTs.
How to read tiers A–F
Evidence tiers belong to the drug-indication pair, not to the drug as a whole: the same substance can be A for one condition and F for another.
- AStrong evidence – first or second line in international guidelines
- BRecommended in selected cases
- CStudy data contradict each other
- DBenefit not proven, no documented harm
- FDocumented harm, or risk without benefit